Scientific Advisory Board
David S. Boyer, MD
Founder, Retina-Vitreous Associates Medical Group
Dr. Boyer is a world-renowned clinician, surgeon and educator. He is the founder of Retina-Vitreous Associates Medical Group with six locations in Southern California. He received a BS from the University of Illinois at Champaign, after which he completed a medical degree at the Chicago Medical School. In 1976 he finished his residency at U.S.C. County Medical Center’s Doheny Eye Institute. A year long retinal surgery fellowship at the Wills Eye Hospital, located in Philadelphia, completed his training. He is currently a leading investigator for various national clinical trials on retinal diseases and serves as an advisor for multiple research, educational and charitable institutions.
Peter Campochiaro, MD
George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute at Johns Hopkins School of Medicine.
Dr. Campochiaro was trained at the University of Notre Dame, Johns Hopkins School of Medicine, the University of Virginia, and Wilmer Eye Institute at Johns Hopkins School of Medicine, joining the Wilmer Faculty in 1991. He is currently the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute. His major research interests are in gaining a greater understanding of the roles of peptide growth and trophic factors in the retina and retinal pigmented-epithelium with an ultimate goal of developing new treatments for proliferative retinopathies, choroidal neovascularization, and retinal degenerations. Dr. Campochiaro is a distinguished member of numerous societies, including the American Academy of Ophthalmology, Macula Society, Retina Society, International Society for Eye Research.
Jeffrey S. Heier, MD
Director of the Vitreoretinal Service at Ophthalmic Consultants of Boston, and Co-director of the Vitreoretinal Fellowship.
Dr. Heier is the Director of the Vitreoretinal Service at Ophthalmic Consultants of Boston, and Co-director of the Vitreoretinal Fellowship. He is the Secretary of Online Education for the American Academy of Ophthalmology and the past President of the Center for Eye Research and Education in Boston, MA. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He serves on the Scientific Advisory Board or as Clinical Design Consultant to over twenty biotechnical or pharmaceutical companies, lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases, and has authored numerous works in peer-reviewed journals.
Dr. Heier received his medical degree from Boston University, then did his transitional internship and ophthalmology residency at Fitzsimons Army Medical Center. Between his internship and residency, Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, for which he was awarded a Bronze Star. Dr. Heier then completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine.
Peter K. Kaiser, MD
Staff member of the vitreoretinal faculty of the Cole Eye Institute in the Department of Ophthalmology at Cleveland Clinic and Founding Director of the Digital Optical Coherence Tomography Reading Center (DOCTR) at the Cole Eye Institute.
Peter K. Kaiser, MD graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School. He completed an internal medicine internship at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, and a vitreoretinal fellowship at Bascom Palmer Eye Institute before joining the vitreoretinal department of the Cole Eye Institute at the Cleveland Clinic Foundation, Cleveland, Ohio where he is the Chaney Family Endowed Professor of Ophthalmology Research at the Cleveland Clinic Lerner College of Medicine.
As a National Eye Institute and National Institute of Health RO1-funded principle investigator, Dr. Kaiser leads a team involved in the evaluation of vascular biology in age-related macular degeneration (AMD) and diabetic retinopathy (DR). In addition, Dr Kaiser is actively involved in clinical research having served as Study Chairman for numerous major, multi-center, international clinical trials, and principal investigator in over 60 trials evaluating new treatments for AMD, DR, and other retinal disorders. He is the founder and director of the Digital Optical Coherence Tomography Reading Center (DOCTR), which is the OCT reading center for over 700 international sites and 45 multi-center, clinical trials. Dr. Kaiser has been honored to receive the Lew R. Wasserman Award from the Research to Prevent Blindness for his research. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences. He is a major contributor to the medical literature having authored 7 textbooks, 25 book chapters, and more than 250 peer-reviewed manuscripts. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, and Ocular Surgery News. Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Achievement and Senior Achievement Awards, and has been listed as one of the “Best Doctors in America” since 2002. He is the team ophthalmologist for the Cleveland Browns (National Football League) and Cleveland Cavaliers (National Basketball Association).
Julie Kornfield, PhD
Professor, Department of Chemical Engineering
California Institute of Technology
Dr. Kornfield, Professor of Chemical Engineering at the California Institute of Technology, is an expert in polymer physics, including the physical properties of ocular tissues (cornea, sclera, vitreous), tissue engineering and drug delivery. She has won numerous awards, including the John N. Dillon Medal of the American Physical Society, and is a Fellow of the American Association for the Advancement of Science. She is a co-founder of Calhoun Vision and led the development of the material with the speed, clarity and sensitivity to enable clinically relevant adjustment of the light adjustable lens (LAL). She is a co-founder of Visdex and has led the in vitro studies of efficacy, drug delivery and irradiation for therapeutic cross-linking of the cornea and sclera using eosin Y and visible light.
Barry Kuppermann, MD, PhD
Professor of Ophthalmology and Biomedical Engineering
Chief, Retina Service
Vice-Chair, Clinical Research, Ophthalmology, School of Medicine
University of California, Irvine
After completing his PhD in neuroscience at the California Institute of Technology, Dr. Kuppermann went on to earn an MD at the University of Miami. He interned at LA County/USC Medical Center and did his residency in ophthalmology at USC’s Doheny Eye Institute. Dr. Kuppermann then went on to complete fellowships in Retina at both St. Joseph’s in Baltimore Maryland, and at the University of California, San Diego. Following his fellowships he came to UCI and has been on faculty since 1992. Currently he is an Associate Professor and Chief of the Retina Service at UCI.
Dr. Kuppermann is the principal investigator at UCI for several multicenter national trials evaluating new drugs and devices for the treatment of diabetic retinopathy, age-related macular degeneration, and the ocular complications of AIDS. He is the national and international lead investigator for several of these trials. His primary area of research is drug delivery to the posterior segment of the eye, with special attention to the pharmacokinetics of the posterior segment. He has also developed models for viral retinal infections as well as for retinal angiogenesis and his research on these models using time-release therapeutic agents may lead to new methods for the treatment of potentially blinding infections. In addition, Dr. Kuppermann has extensive research collaborations with pharmaceutical and biotechnology companies, serving as an advisor with a goal of bringing new treatments to patients for a variety of retinal diseases.
Dr Kuppermann is listed as one of the best doctors in America, and for the last several years in a row has been named as the “Best Ophthalmologist in Orange County” by Orange Coast Magazine. Dr. Kuppermann is a peer reviewer for the American Journal of Ophthalmology, Archives of Ophthalmology, Investigative Ophthalmology and Visual Science, Ophthalmology, Retina, Journal of Infectious Diseases, Lancet, and the Journal of Obstetrics and Gynecology.
Hugo Quiroz-Mercado, MD
Director of Ophthalmology Vitreo-Retina Specialist, Denver Health Medical Center
Professor of Ophthalmology, University of Colorado School of Medicine
Ophthalmologist, Hospital Médica Sur
Consultant for Clinical Research Asociación Para Evitar la Ceguera en México, I.A.P.
Dr. Hugo Quiroz-Mercado is a board-certified ophthalmologist specializing in diabetic retinopathy and retinopathy of prematurity as the Director of Ophthalmology Service at Denver Health Medical Center. With over 25 years of practice experience, Dr. Mercado has held previous appointments as the Director of the Retina Department and Chief of the Experimental Surgery Laboratory at Luis Sanchez Hospital for the Prevention of Blindness, as well as a professor of Ophthalmology at the Facultad de Medicine Universidad Autonoma de Mexico. He specializes in treating patients with severe retinopathy and helping them cope with the impending complications.
Dr. Mercado completed his medical degree at Facultad de Medicine Universidad Nacional Automa de Mexico, and completed his postgraduate residency at Luis Sanchez Hospital for the Prevention of Blindness in Mexico City. Dr. Mercado then furthered his training by completing fellowships in Vitreo-Retinal Diseases at APEC in Mexico City and Schepens Eye Research Institute in Boston.